Alaunos Therapeutics, Inc.
NASDAQ: TCRT0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Holger Weis
- Employees
- 1
- Headquarters
- Houston, United States
- IPO year
- 2005
- Market cap
- $5.3M
- Website
- https://www.alaunos.com
Loading TCRT…
Loading profile data…Frequently asked questions about TCRT
What does Alaunos Therapeutics, Inc. (TCRT) do?
Alaunos Therapeutics, Inc. is an oncology company in the clinical trial phase, specializing in the creation of adoptive T-cell receptor (TCR) engineered therapies. Their pipeline includes a TCR Library, currently undergoing Phase I/II clinical trials, which comprises ten T-cell receptors designed to target mutated KRAS, TP53, and EGFR in various...
Where does TCRT trade?
Alaunos Therapeutics, Inc. (TCRT) trades on the NASDAQ Global Select.
What sector is TCRT in?
Alaunos Therapeutics, Inc. (TCRT) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Alaunos Therapeutics, Inc.?
Holger Weis is the chief executive officer of Alaunos Therapeutics, Inc. (TCRT).
Where is Alaunos Therapeutics, Inc. headquartered?
Alaunos Therapeutics, Inc. is headquartered in United States.
Does TCRT pay a dividend?
Alaunos Therapeutics, Inc. (TCRT) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did TCRT go public?
Alaunos Therapeutics, Inc. (TCRT) completed its initial public offering in 2005.